While increased myocardial ketone body oxidation is a postulated mechanism by which SGLT2 inhibitors improve cardiovascular outcomes in T2D, careful consideration should be taken with regards to systemically boosting ketone body oxidation in humans with T2D, as increases in skeletal muscle ketone body oxidation appear to promote hyperglycemia (Al Batran et al., 2020). Here, SLC5A2 is linked to type 2 diabetes mellitus.